If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection
100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Is there an Emgality® (galcanezumab-gnlm) pregnancy registry?
An Emgality (galcanezumab) pregnancy exposure registry is currently available in the United States. A subsequent observational study will compare maternal, fetal, and infant outcomes. Information about the registry and study is provided below.
Pregnancy Registry and Observational Study Will Compare Maternal, Fetal, and Infant Outcomes
A pregnancy exposure registry and subsequent registry-based prospective observational study in the United States will compare maternal, fetal, and infant outcomes.
This study will enroll mothers with live births into each of the following groups:
- women with migraine exposed to galcanezumab up to 5 months before or during pregnancy
- pregnant women with migraine exposed to other migraine preventative medications, and
- pregnant women with migraine not exposed to migraine preventative medications.1
Lilly Migraine Pregnancy Registry Enrollment Information
Eligible women may self-enroll, or be enrolled by their healthcare provider into the Lilly Migraine Pregnancy Registry by
- accessing the registry website at www.migrainepregnancyregistry.com, or
- calling 1-833-464-4724.1,2
This registry is only available in the United States.
Enclosed Prescribing Information
Reference
1Ephross SA, Schroeder KM, Kellier-Steele NA, et al. Registry-based, prospective, observational study to assess maternal, fetal, and infant outcomes following exposure to migraine treatments, including galcanezumab. Poster presented at: Diamond Headache Clinic Research & Educational Foundation; July 15-18, 2021; Lake Buena Vista, FL.
2Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: March 15, 2023